QIAGEN CEO Thierry Bernard named Chairman of AdvaMedDx Board of Directors

April 3, 2023
Industry news.

AdvaMedDx, a division of AdvaMed representing more than 75 manufacturers of innovative in vitro diagnostic (IVD) tests and technologies in the U.S. and abroad, announced that Thierry Bernard, CEO of QIAGEN, was elected Chair of the AdvaMedDx Board of Directors. He succeeds Norman Schwartz, CEO of Bio-Rad Laboratories.

Bernard joined QIAGEN in 2015 and was named CEO in 2019. Previously, he worked for 15 years at bioMérieux, where he served in many roles, including as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region.

AdvaMed release

BrAt_PiKaChU iStock / Getty Images Plus Getty Images
6712c6754e7816a269c237d5gettyimages1065742978
BrAt_PiKaChU iStock / Getty Images Plus Getty Images
gettyimages1065742978
ID 68975377 © Alexander Kharchenko | Dreamstime.com
dreamstime_xxl_68975377